Literature DB >> 10499335

Enantioseparation of thalidomide and its hydroxylated metabolites using capillary electrophoresis with various cyclodextrins and their combinations as chiral buffer additives.

M Meyring1, B Chankvetadze, G Blaschke.   

Abstract

The separation of thalidomide (TD) and its hydroxylated metabolites including their simultaneous enantioseparation was studied in capillary electrophoresis (CE) using four different randomly substituted charged cyclodextrin (CD) derivatives, the combinations of some of them with each other, and beta-CD. TD, as well as two metabolites recently found in incubations of human liver microsomes and human blood, 5-hydroxythalidomide (5-OH-TD) and one of the diastereomeric 5'-hydroxythalidomides (5'-OH-TD), are neutral compounds. Therefore, they were resolved using charged chiral selectors in CE. Two different separation modes (normal polarity and carrier mode) and two different capillaries (fused-silica and polyacrylamide-coated) were tested. Based on the behavior of the individual CDs, their designed combinations were selected in order to improve the separation selectivity and enantioselectivity. Under optimized conditions all three chiral compounds and their enantiomers were resolved simultaneously.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499335     DOI: 10.1002/(SICI)1522-2683(19990801)20:12<2425::AID-ELPS2425>3.0.CO;2-W

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  2 in total

1.  Combined use of chiral ionic liquid surfactants and neutral cyclodextrins: evaluation of ionic liquid head groups for enantioseparation of neutral compounds in capillary electrophoresis.

Authors:  Yijin Liu; Shahab A Shamsi
Journal:  J Chromatogr A       Date:  2014-07-24       Impact factor: 4.759

2.  Optimized separation of beta-blockers with multiple chiral centers using capillary electrochromatography-mass spectrometry.

Authors:  William Bragg; Dean Norton; Shahab A Shamsi
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-11-01       Impact factor: 3.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.